Ignite Creation Date:
2024-05-06 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06178250
Status:
COMPLETED
Last Update Posted:
2023-12-20
First Post:
2023-12-03
Brief Title:
Placenta Fetal Liver Sectional Ductus Venosus Volumes Examined by Three-dimensional Ultrasound in the Second Trimester
Sponsor:
Sanliurfa Mehmet Akif Inan Education and Research Hospital
Organization:
Sanliurfa Mehmet Akif Inan Education and Research Hospital
Study Overview
Official Title:
The Role of Placenta Fetal Liver Sectional Ductus Venosus Volumes Examined by Three-dimensional Ultrasound in the Second Trimester in Predicting Gestational Diabetes Mellitus and Maternal-fetal Outcomes
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Investigators measured the placenta fetal liver and ductus venosus volumes of pregnant women with GDM diagnosis and normal glycemic indices in the second trimesterInvestigators aimed to correlate measurements with maternalfetal outcomes and evaluate their success in predicting poor obstetric outcomes
Detailed Description:
GDM screening may not always be possible with OGTT performed in limited weeks of gestation In addition mid-trimester ultrasound scanning is done in all pregnancies Therefore measurement of placental volume and fetal liver volume may be an alternative method for the diagnosis of GDM In order to predict GDM in the second trimester the use of 3D sonography and VOCAL Virtual Organ Computer Aided Analysis technology in high-risk pregnant women and their cost-effectiveness rates should be investigated further Multicenter randomized controlled studies with more patients are needed to be able to say more clearly
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None